Issue 4/2025
Content (11 Articles)
Progress and Challenges in the Treatment of Fabry Disease
- Open Access
- Fabry Disease
- Leading Article
Malte Lenders, Elise Raphaela Menke, Eva Brand
Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings
- Open Access
- Filgrastim
- Review Article
Tore K. Kvien, Neil Betteridge, Ines Brückmann, Wolfram Bodenmüller, Galyna Bryn, Silvio Danese, João Gonçalves, Zorana Maravic, Carter Thorne, Laura Wingate, Paul Cornes
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy
- Osteoarthrosis
- Review Article
Qiming Pang, Jingdi Zhan, Zhuolin Chen, Lili Dong, Wei Huang
Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders
- Open Access
- Review Article
Angela H. Holian, Brian G. Weinshenker
Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians
- Open Access
- Adalimumab
- Review Article
John R. P. Tesser, Aline Charabaty, Adelaide A. Hebert
The Use of Biologics for Thyroid Eye Disease
- Diplopia
- Review Article
Shoaib Ugradar, Emanuil Parunakian, Raymond S. Douglas
Interrogation of Structure–Activity Relationships in Charge Variants of Therapeutic IgG2s Enabled by Free-Flow Isoelectric Focusing Fractionation
- Denosumab
- Original Research Article
Lingyu Wang, Yajun Zeng, Wenyuan Gao, Pengcheng Shen, Ping Han, Zhongli Zhang
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?
- Open Access
- Infliximab
- Original Research Article
Gyeongseon Shin, Heejin Han, Gyeyoung Choi, Donghwan Lee, SeungJin Bae
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase
- Open Access
- Etanercept
- Original Research Article
Hiroko Shibata, Akira Harazono, Masato Kiyoshi, Yoshiro Saito, Akiko Ishii-Watabe
Comment on “Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review”
- Open Access
- Letter to the Editor
Joao Goncalves, Paolo Caliceti
Author’s Reply to Gonçalves: “Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review”
- Open Access
- Letter to the Editor
Chae Sung Lee
